var docs;if (!docs) docs =[]; docs["63"]={"6300":"<p><b>Title</b> Ticagrelor / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors. Itraconazole US prescribing information lists its use with ticagrelor as contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the ticagrelor Canadian product monograph and U.S. prescribing information, coadministration of ketoconazole (200 mg twice/day) with ticagrelor increased ticagrelor maximum concentration (Cmax) and AUC by 2.4- and 7.3-fold, respectively, while the Cmax and AUC of its active metabolite were reduced by 89% and 56%, respectively.<sup>1,2</sup> The presumed primary mechanism of this interaction is ketoconazole inhibition of CYP3A-mediated ticagrelor metabolism, although ketoconazole inhibition of p-glycoprotein mediated ticagrelor transport may also contribute to increased concentrations of the parent drug. The Canadian product monograph lists coadministration of ticagrelor with any strong CYP3A4 inhibitor as contraindicated,<sup>1</sup> and the U.S. prescribing information recommends avoiding concurrent use with any strong CYP3A4 inhibitors.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., May 2011.</p>\n<p>2. Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6301":"<p><b>Title</b> Digoxin / Ticagrelor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ticagrelor may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased digoxin concentrations and effects in patients receiving ticagrelor.</p> \n<p><b>Discussion</b> In a clinical study summarized in the ticagrelor Canadian product monograph, coadministration of ticagrelor with digoxin increased digoxin maximum concentration and AUC by 75% and 28%, respectively.<sup>1</sup> The presumed primary mechanism of this interaction is ticagrelor inhibition of p-glycoprotein mediated digoxin transport.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Brilinta (ticagrelor). Mississauga, ON: AstraZeneca Canada Inc., May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6302":"<p><b>Title</b> Ticagrelor / Aspirin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: While daily low dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg/day) is recommended with ticagrelor, ticagrelor benefits appear to be diminished relative to clopidogrel in patients receiving higher aspirin doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in adult patients receiving daily aspirin doses greater than 100-150 mg daily. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid maintenance aspirin doses greater than 100 mg/day in patients receiving ticagrelor. After any initial dose, only low-dose aspirin (75-100 mg/day) is recommended. Of note, the Canadian ticagrelor product monograph recommendations are slightly different, recommending that maintenance aspirin doses should be 75-150 mg/day and that aspirin doses greater than 150 mg/day should be avoided.</p> \n<p><b>Discussion</b> According to the U.S. prescribing information for ticagrelor, maintenance doses of aspirin greater than 100 mg/day may decrease the effectiveness of ticagrelor and should be avoided.<sup>1</sup> The Canadian product monograph for ticagrelor recommends avoiding maintenance doses of aspirin greater than 150 mg/day.<sup>2</sup> These recommendations are largely based on a post-hoc analysis of the PLATO large clinical trial supporting the relative efficacy of ticagrelor.<sup>1,2,3,4</sup> In this analysis, geographic differences in ticagrelor benefits were largely attributed to regional differences in aspirin doses.<sup>4</sup> Of note, there are at least some questions about the validity of this conclusion, with regional differences in study oversight raised as an alternative explanation for the observed variability in the PLATO trial,<sup>5</sup> and others have similarly questioned the validity of these recommendations for diabetic patients.<sup>6</sup><br><br>The precise mechanism for this possible interaction between higher dose aspirin and ticagrelor is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011.</p>\n<p>2. Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., May 2011.</p>\n<p>3. Mahaffey KW, Wojdyla DM, Carroll K, et al, “Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial,” <i>Circulation</i>, 2011, Jun 27 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21709065\">[PubMed 21709065]</a></p>\n<p>4. Wallentin L, Becker RC, Budaj A, et al, “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” <i>N Engl J Med</i>, 2009, 361(11):1045-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19717846\">[PubMed 19717846]</a></p>\n<p>5. Serebruany VL, “Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?” <i>Cardiology</i>, 2010, 117(4):280-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21304245\">[PubMed 21304245]</a></p>\n<p>6. Dinicolantonio JJ, Serebruany VL, “Challenging the FDA Black Box Warning for High Aspirin Dose with Ticagrelor in Patients with Diabetes,” <i>Diabetes</i>, 2013,62(3):669-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23431005\">[PubMed 23431005]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6303":"<p><b>Title</b> Simvastatin / Ticagrelor</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ticagrelor may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor. Monitor for increased systemic effects of simvastatin in patients receiving concurrent ticagrelor. Of note, this recommendation to limit simvastatin dose is specific to U.S. prescribing information. Though the Canadian product monograph does warn about this interaction, it does not contain the same specific recommendation.</p> \n<p><b>Discussion</b> In a clinical study summarized in the ticagrelor Canadian product monograph, coadministration of ticagrelor with simvastatin increased the maximum concentration and AUC of simvastatin (by 81% and 56%, respectively) and simvastatin acid (by 64% and 52%, respectively).<sup>1</sup> Some individual AUC increases of 2-3 fold were observed. The mechanism of this interaction is unclear. The product monograph suggests a similar interaction with lovastatin, but not with other statins.<br><br>The U.S. prescribing information recommends limiting the dose of lovastatin to 40 mg/day or less with ticagrelor.<sup>2</sup> Though the Canadian product monograph does warn about this interaction, it does not contain the same specific recommendation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., May 2011.</p>\n<p>2. Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6304":"<p><b>Title</b> Lovastatin / Ticagrelor</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ticagrelor may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid using doses of lovastatin greater than 40 mg/day with ticagrelor. Monitor for increased systemic effects of lovastatin in patients receiving concurrent ticagrelor. Of note, this recommendation to limit lovastatin dose is specific to U.S. prescribing information. Though the Canadian product monograph does warn about this interaction, it does not contain the same specific recommendation.</p> \n<p><b>Discussion</b> In a clinical study summarized in the ticagrelor Canadian product monograph, coadministration of ticagrelor with simvastatin increased the maximum concentration and AUC of simvastatin (by 81% and 56%, respectively) and simvastatin acid (by 64% and 52%, respectively).<sup>1</sup> Some individual AUC increases of 2-3 fold were observed. The mechanism of this interaction is unclear. The product monograph suggests a similar interaction with lovastatin, but not with other statins. <br><br>The U.S. prescribing information recommends limiting the dose of lovastatin to 40 mg/day or less with ticagrelor.<sup>2</sup> Though the Canadian product monograph does warn about this interaction, it does not contain the same specific recommendation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., May 2011.</p>\n<p>2. Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6307":"<p><b>Title</b> Pizotifen / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of pizotifen with monoamine oxidase inhibitors is contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Due to weak anticholinergic effects associated with pizotifen, the manufacturer labeling contraindicates concomitant use of pizotifen and monoamine oxidase inhibitors.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Sandomigran (pizotifen). Montreal, Quebec: Paladin Labs Inc., June 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6308":"<p><b>Title</b> Belimumab / Belatacept</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Belatacept may enhance the adverse/toxic effect of Belimumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of belimumab with other biologic therapies, such as belatacept, is not recommended.</p> \n<p><b>Discussion</b> According to the belimumab prescribing information, since belimumab has not been studied in combination with other biologic agents, such concurrent use is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Benlysta (belimumab). Rockville, MD: Human Genome Sciences, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6310":"<p><b>Title</b> Rivaroxaban / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The Canadian product monograph does not specifically recommend avoiding this combination but does recommend caution.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of rivaroxaban and strong inducers of CYP3A4 and P-glycoprotein (P-gp) when possible. US prescribing information recommends avoiding concurrent use of rivaroxaban and drugs that are strong inducers of both CYP3A4 and P-gp. Some non-US labeling recommends caution when such combinations are used, but does not make specific recommendations for management. Increase monitoring of clinical response to rivaroxaban with any such combination. CYP3A4 inducers that are not inducers of the P-gp transporter may interact to a less significant degree.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Average rivaroxaban AUC and maximum serum concentration (Cmax) were approximately 50% and 22% lower, respectively, when a single rivaroxaban dose (20 mg) was administered to individuals who were taking rifampin (titrated up to 600 mg/day).<sup>1,2</sup> Proportional decreases in the effects of rivaroxaban were also noted.<sup>1</sup> Published case reports describe a 67-year-old woman who died with extensive pulmonary emboli following use of rivaroxaban in combination with rifampin,<sup>3</sup> and a 55-year-old man who experienced a recurrent deep venous thrombosis and reduced rivaroxaban concentrations when rivaroxaban was combined with carbamazepine.<sup>4</sup><br><br>The suspected primary mechanism of these interactions is rifampin induction of both CYP3A4-mediated metabolism and P-glycoprotein-mediated efflux of rivaroxaban. US labeling recommends avoiding concurrent use of rivaroxaban and any drugs that are strong inducers of both CYP3A4 and P-glycoprotein.<sup>1</sup> Canadian labeling for rivaroxaban recommends caution with the use of rivaroxaban with any strong inducer of CYP3A4 and P-glycoprotein.<sup>2</sup> Since many strong CYP3A4 inducers are also inducers of P-glycoprotein, such caution with the concurrent use of any strong CYP3A4 inducer appears warranted.<br><br>In contrast to these data suggesting decreased rivaroxaban effects with concurrent use of inducers of both CYP3A4 and P-glycoprotein, the use of rifampin or phenytoin was associated with a 1.57- or 1.94-fold increase in incidence rate ratio for major bleeding according a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with rivaroxaban (59.13% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, dabigatran or apixaban).<sup>5</sup> Concurrent rifampin or phenytoin was associated with an increase of 36.9 and 52.3 major bleeding episodes per 1000 person-years. Several other examined combinations also yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear, but increased monitoring of patients for evidence of either a decreased or an increased anticoagulant response seems to be warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc.; March 2017.</p>\n<p>2. Xarelto (rivaroxaban) [product monograph]. Toronto, Ontario, Canada: Bayer Inc.; July 2015.</p>\n<p>3. Altena R, van Roon E, Folkeringa R, de Wit H, Hoogendoorn M. Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica. 2014;99(2):e26-e27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24497568\">[PubMed 24497568]</a></p>\n<p>4. Stollberger C, Finsterer J. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. Neurol Neurochir Pol. 2017;51(2):194-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28215696\">[PubMed 28215696]</a></p>\n<p>5. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6311":"<p><b>Title</b> Rivaroxaban / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The Canadian product monograph does not specifically recommend avoiding this combination but does recommend caution.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Rivaroxaban. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of rivaroxaban and St Johns Wort. The U.S. prescribing information recommends avoiding concurrent use of rivaroxaban and any drugs that are strong inducers of both CYP3A4 and P-glycoprotein (such as St Johns Wort). The Canadian product monograph recommends caution when such combinations are used, but does not make specific recommendations regarding any dose adjustments. Increase monitoring of clinical response to rivaroxaban if this combination must be used.</p> \n<p><b>Discussion</b> Though specific data regarding this combination are not available, average rivaroxaban AUC and maximum serum concentration (Cmax) were approximately 50% and 22% lower, respectively, when a single rivaroxaban dose (20 mg) was administered to individuals who were taking the rifampin (titrated up to 600 mg/day), which, like St Johns Wort, is an inducer of CYP3A4 and P-glycoprotein.<sup>1,2</sup> Proportional decreases in the effects of rivaroxaban were also noted.<sup>1</sup> Based on these results and the fact that both CYP3A4 and P-glycoprotein are involved in the elimination and disposition of rivaroxaban, U.S. prescribing information recommends avoiding concurrent use of St Johns Wort and rivaroxaban, while Canadian labeling recommends caution when considering the use of rivaroxaban with any strong inducer of CYP3A4 and P-glycoprotein (such as St. Johns wort).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xarelto (rivaroxaban). Titusville, NJ: Janssen Pharmaceuticals, Inc., July 2011.</p>\n<p>2. Product monograph. Xarelto (rivaroxaban). Toronto, Ontario, Canada: Bayer Inc., September 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6312":"<p><b>Title</b> Rivaroxaban / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended, and UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. US and Canadian rivaroxaban labeling recommend caution and increased monitoring if used with any antiplatelet agent. Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended. Any combined use should only be undertaken with increased monitoring for evidence of bleeding.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> When added to patients with acute coronary syndrome who were taking aspirin alone or aspirin plus a thienopyridine, rivaroxaban use was associated with a dose-dependent increase in the risk for bleeding (hazard ratio [HR] = 2.2 to 5.1 for doses from 5 mg to 20 mg/day) compared to placebo (n=3491).<sup>1</sup> In an analysis combining trials for the use of rivaroxaban for the treatment of venous thromboembolism, clinically relevant major bleeding increased with nonsteroidal anti-inflammatory drug (NSAID) use (HR, 1.90 [95% CI, 1.45-2.49]) and aspirin use (HR, 1.81 [95% CI, 1.36-2.42) compared with rivaroxaban alone.<sup>2</sup>. Product labeling also lists aspirin use as an independent risk factor for bleeding and concurrent use of rivaroxaban (15 mg/day) with clopidogrel (300 mg loading dose, then 75 mg/day) was associated with an approximate doubling of bleeding time in 30%-45% of patients in 2 separate studies.<sup>3,4</sup> In contrast, a study in healthy volunteers concluded that there were no pharmacokinetic or pharmacodynamic interactions between aspirin and rivaroxaban.<sup>5</sup><br><br>Rivaroxaban labeling cautions that concomitant aspirin use has been identified as an independent risk factor for major bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Caution and increased monitoring for bleeding should be exercised if rivaroxaban is combined with any antiplatelet agent.<sup>2</sup> The rivaroxaban Canadian product monograph recommends avoiding concomitant use of rivaroxaban with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet</i>. 2009;374(9683):29-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19539361\">[PubMed 19539361]</a></p>\n<p>2. Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin [published online April 14, 2014]. <i>JAMA Intern Med</i>. doi: 10.1001/jamainternmed.2014.946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24733305\">[PubMed 24733305]</a></p>\n<p>3. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2015.</p>\n<p>4. Xarelto (rivaroxaban) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc.; May 2015.</p>\n<p>5. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. <i>J Clin Pharmacol</i>. 2006;46(9):981-990. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920892\">[PubMed 16920892]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6313":"<p><b>Title</b> Rivaroxaban / Anticoagulants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased risk for bleeding.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin<br><b>Exceptions</b> Acenocoumarol, Warfarin</p>\n</div> \n<p><b>Discussion</b> According to rivaroxaban prescribing information, combined administration of single doses of rivaroxaban (10 mg) and enoxaparin (40 mg subcutaneously) was associated with an apparent additive anti-factor Xa effect.<sup>1</sup> This combination was not associated with any evidence of a pharmacokinetic interaction. Similarly, combined use of single doses of rivaroxaban (5 mg) and warfarin (15 mg) was associated with an additive anti-factor Xa effect and additive PT/INR-lowering.<sup>1</sup> There was no evidence of a pharmacokinetic interaction between these agents.<br><br>Rivaroxaban labeling cautions that concurrent use with antiplatelet, anticoagulant, or antithrombotic agents has not been adequately studied and that such combinations may increase the risk for bleeding.<sup>1,2</sup> The Canadian product monograph recommends avoiding such combinations whenever possible,<sup>2</sup> and the U.S. prescribing information recommends avoiding concurrent use with anticoagulants other than during transition periods, during which time patients should be closely monitored for evidence of bleeding.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xarelto (rivaroxaban). Titusville, NJ: Janssen Pharmaceuticals, Inc., July 2011.</p>\n<p>2. Product monograph. Xarelto (rivaroxaban). Toronto, Ontario, Canada: Bayer Inc., September 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6314":"<p><b>Title</b> Rivaroxaban / Clarithromycin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of this warning and the recommended management varies between US and Canadian labeling, with a slightly stronger warning in the US prescribing information.</p></li>\n <li><p><b>Renal Function</b>: This interaction is likely of much greater significance in patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Rivaroxaban. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients with normal renal function the small increases in rivaroxaban concentrations are likely clinically insignificant, though monitoring for bleeding should occur. However, in patients with impaired renal function (ie, CrCl 15-80 mL/min) who are receiving rivaroxaban, the US prescribing information warns that moderate inhibitors of P-glycoprotein and CYP3A4 should not be used unless the potential benefits outweigh the potential risks. The warning in at least some non-US labeling for rivaroxaban is not as strong, though it does warn that patients with moderately impaired renal function (ie, CrCl 30-49 mL/min) should use added caution when using rivaroxaban, particularly with concurrent use of drugs that can increase rivaroxaban concentrations.</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with rivaroxaban (59.13% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, dabigatran or apixaban), concurrent use of clarithromycin or erythromycin was associated with a 40% decrease in the incidence rate ratio for major bleeding.<sup>1</sup> Of note, several other combinations examined in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>Concomitant use of single-dose rivaroxaban with clarithromycin resulted in a 50% increase in mean rivaroxaban AUC and a 40% increase in mean maximum serum concentration (Cmax).<sup>2,3</sup> This finding was somewhat unexpected considering that clarithromycin is considered both a P-glycoprotein (P-gp) inhibitor and a strong inhibitor of CYP3A4, and other such combined inhibitors (ie, ketoconazole, ritonavir) have been associated with 150% to 160% increases in rivaroxaban AUC with coadministration.<sup>2</sup> According to rivaroxaban prescribing information, this unexpected finding may be the result of relatively weak P-gp inhibition by clarithromycin, leading to increases in serum rivaroxaban concentrations similar to moderate inhibitors of P-gp and CYP3A4 (eg, erythromycin, fluconazole).<br><br>Rivaroxaban is both a CYP3A4 and P-gp substrate, and its elimination is partially dependent on normal renal function. Since the interaction is expected to be of greater severity and significance in patients with impaired renal function, extra caution is warranted.<sup>2</sup> Consistent with this, the rivaroxaban AUC was increased by approximately 1.8- to 2-fold in patients with either mildy (CrCl 50-79 mL/min) or moderately (CrCl 30-49 mL/min) impaired renal function who were given erythromycin, respectively, as compared to patients with normal renal function not receiving erythromycin.<sup>2</sup> This apparent interaction is most likely the result of clarithromycin-mediated inhibition of both CYP3A4 and P-gp.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2017.</p>\n<p>3. Xarelto (rivaroxaban) [product monograph]. Toronto, Ontario, Canada: Bayer Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6315":"<p><b>Title</b> Warfarin / QUEtiapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QUEtiapine may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Increase monitoring of INR and signs/symptoms of bleeding for several weeks after starting quetiapine or after increasing quetiapine dose. Similarly, quetiapine discontinuation and/or dose reduction may also be associated with changes in INR and warfarin dose requirements.</p> \n<p><b>Discussion</b> One published case report describes a 71-year-old female whose INR increased to 9.2 two weeks after starting quetiapine 200 mg/day.<sup>1</sup> Of note, her INR was 2.7 five days after starting quetiapine, and both her warfarin dose and INR appeared to have varied somewhat (from 12.5 mg to 20 mg/week and from 1.6 to 2.6, respectively) for no discernable reason in the months prior to this elevated INR. Though the report certainly does suggest a possible interaction with quetiapine due to the timing of this event, the possibly significant contribution of other factors can not be excluded.<br><br>Another published case report describes a 78-year-old man who had been treated with warfarin (INR 1.02-2) who presented with multiple intracerebral hemorrhages and an elevated INR (3.54 at presentation, and 10.8 after admission to intensive care) three days after starting treatment with quetiapine 12.5 mg/day.<sup>2</sup> Of note in this case is the very low dose of quetiapine and the much more rapid onset of INR change in this case compared to the other published report (3 days in this case vs. INR normal at 3 days but elevated at 14 days in the other report).<sup>1,2</sup><br><br>The mechanism for any potential interaction between quetiapine and warfarin is uncertain. Quetiapine is primarily metabolized by CYP3A, with some involvement of CYP2D6 and CYP2C9, and available data suggest that it is not an inhibitor of these or other cytochrome P450 enzymes.<sup>3</sup> Warfarin is metabolized by several different enzymes, with CYP2C9 having the most significant role. Competitive inhibition of warfarin metabolism and/or protein-binding displacement have been proposed as possible mechanisms,<sup>1,2</sup> but evidence to support such are lacking, and particularly with the very low dose of quetiapine reported in one of the cases, such a mechanism seems unlikely.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rogers T, de Leon J, Atcher D, “Possible Interaction Between Warfarin and Quetiapine,” <i>J Clin Psychopharmacol</i>, 1999, 19(4):382-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10440472\">[PubMed 10440472]</a></p>\n<p>2. Yang FW, Liang CS, “Multiple Intracerebral Hemorrhages in an Elderly Patient After Adding Quetiapine to a Stable Warfarin Regimen,” <i>Gen Hosp Psychiatry</i>, 2011, 33(3):302. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21601733\">[PubMed 21601733]</a></p>\n<p>3. Prescribing information. Seroquel (quetiapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, 05/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6328":"<p><b>Title</b> Furosemide / Sucralfate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction appears limited to orally administered furosemide.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.</p> \n<p><b>Discussion</b> Furosemide Canadian product monograph states that concomitant administration (via the oral route) with sucralfate should be avoided as sucralfate may reduce furosemide absorption.<sup>1</sup> Furosemide U.S. prescribing information recommends separating oral administration of these two agents by at least 2 hours.<sup>2</sup> Human data appears to be lacking in regards to this proposed interaction, however, a significant effect on furosemide absorption, urinary excretion, or its natriuretic effect was not observed in an animal study.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Lasix (furosemide). Laval, Quebec: Sanofi-Aventis Canada Inc., August 2010.</p>\n<p>2. Prescribing information. Lasix (furosemide). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, January 2011.</p>\n<p>3. Hikal AH, Walker LA, and Ramachandran T, “In Vitro and In Vivo Interactions of Furosemide and Sucralfate,” <i>Pharm Res</i>, 1987, 4(2):171-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3509143\">[PubMed 3509143]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6329":"<p><b>Title</b> Chloral Hydrate / Furosemide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Furosemide may enhance the adverse/toxic effect of Chloral Hydrate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Furosemide U.S. and Canadian product labeling recommend against concurrent use with chloral hydrate. This recommendation is based on isolated reports of adverse events (diaphoresis, hypertensive and tachycardic effects, restlessness) following IV administration of furosemide to patients receiving chloral hydrate.</p> \n<p><b>Discussion</b> A case report describes a 68-year-old woman who received furosemide 80 mg IV 1 hour before and 12 hours after receiving chloral hydrate 500 mg and experienced flushing, tachycardia, increased blood pressure, and diaphoresis immediately after the second furosemide dose.<sup>1</sup> For the next several days the patient received furosemide, but no chloral hydrate, without incident. On day 5, the patient experienced recurrence of the prior symptoms 8 hours after chloral hydrate 500 mg and immediately after receiving furosemide 40 mg IV. A case report describes similar symptoms (diaphoresis, tachycardia, and agitation) within 5 minutes of IV administration of furosemide to an 8-year-old male receiving chloral hydrate.<sup>2</sup> A resolution of symptoms was observed within 15-20 minutes.<br><br>The specific mechanism for this is uncertain, but it has been proposed that trichloroacetic acid, a highly protein-bound metabolite of chloral hydrate, may displace thyroxin from its protein binding sites resulting in a hypermetabolic state.<sup>1</sup> The U.S. and Canadian furosemide product labeling recommend against concurrent use of furosemide with chloral hydrate.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Malach M, Berman N. Furosemide and chloral hydrate. Adverse drug interaction. <i>JAMA</i>. 1975;232(6):638-639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1173156\">[PubMed 1173156]</a></p>\n<p>2. Dean RP, Rudinsky BF, Kelleher MD. Interaction of chloral hydrate and intravenous furosemide in a child. <i>Clin Pharm</i>. 1991;10(5):385-387. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2049901\">[PubMed 2049901]</a></p>\n<p>3. Lasix (furosemide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, January 2011.</p>\n<p>4. Lasix (furosemide) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6330":"<p><b>Title</b> Loop Diuretics / CycloSPORINE (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction likely applies only to cyclosporine administered via systemic route. Does not apply to topically applied cyclosporine</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for hyperuricemia and/or signs/symptoms of gouty arthritis in patients receiving concomitant loop diuretics and cyclosporine (administered via systemic route).</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In post-renal transplant patients receiving cyclosporine (n=55) or azathioprine (n=23), diuretic (furosemide) use was associated with hyperuricemia and the occurrence of gout in 24% of cyclosporine treated patients.<sup>1</sup> Gout was not observed in azathioprine treated patients. The authors suggest the observed hyperuricemia and gout are likely due to impaired tubular urate clearance due to cyclosporine and increased proximal tubular reabsorption of uric acid due to furosemide induced hypovolemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Noordzij TC, Leunissen KM, and Van Hooff JP, “Renal Handling of Urate and the Incidence of Gouty Arthritis during Cyclosporine and Diuretic Use,” <i>Transplantation</i>, 1991, 52(1):64-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1858156\">[PubMed 1858156]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6331":"<p><b>Title</b> Alcohol (Ethyl) / Varenicline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Varenicline may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may be decreased and the risk for neuropsychiatric adverse effects may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to reduce the amount of alcohol consumed while taking varenicline until they know whether varenicline impacts their alcohol tolerance. Added caution should be used with varenicline in patients who consume alcohol. Specifically, monitor patients closely for evidence of enhanced intoxicating effects and/or other neuropsychiatric adverse effects.</p> \n<p><b>Discussion</b> According to varenicline US and Canadian labeling, patients should be advised to reduce the amount of alcohol they consume while taking varenicline until they know whether it alters their alcohol tolerance.<sup>1,2</sup> Unusual and sometimes aggressive behavior has been reported, as well as amnesia.<sup>1</sup> A March 9, 2015 communication released by the US Food and Drug Administration (FDA) elaborates on these potential risks;<sup>3</sup> since varenicline approval in 2006, FDA received reports of 11 cases of decreased alcohol tolerance and 37 cases of aggressive behavior in patients consuming alcohol while taking varenicline. Alcohol intolerance occurred in patients who tolerated similar alcohol intake prior to varenicline initiation, and 2 cases involved personal injury. Of the 37 cases of aggressive behavior, most were accompanied by a significant change in alcohol response following initiation of varenicline, 22 involved personal harm or property damage, and 16 involved amnesia or incomplete memory loss.<br><br>In addition to the cases reported to FDA, one study in mice found that varenicline may increase alcohol-related ataxia and sedation.<sup>4</sup> In contrast, a review of data from a cohort of 2,682 patients who received a prescription for varenicline cited only a prior history of psychiatric illness as a potential risk factor for an adverse neuropsychiatric effect.<sup>5</sup> Two smaller clinical studies (20 and 30 participants, respectively) of varenicline in heavy drinkers cited the combination as well-tolerated.<sup>6,7</sup> Several papers have also proposed the use of varenicline in patients with alcohol dependence who are smokers based on data suggesting that varenicline may be effective in diminishing alcohol consumption, as well as evidence for a significant role of neuronal nicotinic acetylcholine receptors in the response to alcohol.<sup>6,7,8</sup><br><br>The specific mechanism for this potential interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Chantix</i> (varenicline) [prescribing information]. New York, NY: Pfizer Inc; September 2014.</p>\n<p>2. <i>Champix</i> (varenicline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc.; March 2014.</p>\n<p>3. FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM436960 (accessed March 9, 2015).</p>\n<p>4. Kamens HM, Andersen J, Picciotto MR. The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice. <i>Alcohol Clin Exp Res</i>. 2010;34(12):2053-2060. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20946306\">[PubMed 20946306]</a></p>\n<p>5. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. <i>Drug Saf</i>. 2009;32(6):499-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19459717\">[PubMed 19459717]</a></p>\n<p>6. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. <i>Psychopharmacology (Berl)</i>. 2011;215(4):655-663. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21221531\">[PubMed 21221531]</a></p>\n<p>7. McKee SA, Harrison EL, O'Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. <i>Biol Psychiatry</i>. 2009;66(2):185-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19249750\">[PubMed 19249750]</a></p>\n<p>8. Chatterjee S, Bartlett SE. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. <i>CNS Neurol Disord Drug Targets</i>. 2010;9(1):60-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20201817\">[PubMed 20201817]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6332":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Conivaptan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use with drugs metabolized primarily via CYP3A. Also, initiation of treatment with any drug metabolized primarily via CYP3A should be delayed for at least 7 days following discontinuation of conivaptan.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> According to conivaptan prescribing information, concomitant administration of IV conivaptan (40 mg/day) with midazolam (1 mg IV and 2 mg PO) increased the AUC of IV midazolam 2-fold and of oral midazolam 3-fold.<sup>1</sup> Similarly, IV conivaptan (30 mg/day) increased simvastatin AUC 3-fold while oral conivaptan (40 mg twice daily) increased both the amlodipine AUC and half-life by 2-fold. The manufacturer labeling also describes two cases of rhabdomyolysis in patients receiving oral conivaptan and a CYP3A- metabolized HMG-CoA reductase inhibitor.<br><br>Conivaptan is a moderate CYP3A inhibitor and likely inhibited the metabolism of these agents, and it is expected that conivaptan would have similar effects on other CYP3A4 substrates. As a result, the conivaptan prescribing information recommends avoiding concurrent use with drugs metabolized primarily via CYP3A.<sup>1</sup> Also, initiation of treatment with any drug metabolized primarily via CYP3A should be delayed for at least 7 days following discontinuation of conivaptan.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vaprisol (conivaptan) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6334":"<p><b>Title</b> Loop Diuretics / Methotrexate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Methotrexate may diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for increased methotrexate levels/toxicity and for decreased efficacy and increased toxicity of loop diuretics with concomitant use of these agents. Methotrexate and/or loop diuretic dose reductions may be necessary.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Furosemide prescribing information warns that concomitant administration of methotrexate may decrease furosemide therapeutic effects, increase furosemide and methotrexate systemic exposure, and increase risk of toxicities associated with these agents.<sup>1</sup> Methotrexate and loop diuretics undergo renal tubular secretion and a likely mechanism for the proposed interaction is competition for renal tubular secretion between these agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lasix (furosemide). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6336":"<p><b>Title</b> RisperiDONE / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Where possible, consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Furosemide Canadian product monograph warns that in placebo-controlled trials, elderly patients with dementia receiving concomitant risperidone and furosemide had a higher incidence of mortality (~7%) compared to patients receiving risperidone (~3%) or furosemide (~4%) alone.<sup>1</sup> Similar findings were not observed with concomitant use of risperidone and other diuretics (mostly thiazide diuretics at low doses) nor was a consistent pattern for cause of death observed. Dehydration was an overall risk factor of mortality regardless of treatment, however a mechanism to explain the observations hasn't been determined. Regardless of concomitant use with furosemide, administration of risperidone in elderly patients with dementia-related psychosis has been associated with increased mortality and is not approved for use in this patient population.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Lasix (furosemide). Laval, Quebec: Sanofi-Aventis Canada Inc., August 2010.</p>\n<p>2. Prescribing information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6337":"<p><b>Title</b> Ticagrelor / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Ticagrelor US prescribing information recommends avoiding this combination, while the ticagrelor Canadian product monograph gives no specific management recommendation.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ticagrelor with strong CYP3A4 inducers. This recommendation appears in US prescribing information for ticagrelor, but not in the ticagrelor Canadian product monograph.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 14 healthy volunteers, coadministration of rifampin (600 mg orally daily for 14 days) decreased the maximum concentration and AUC of ticagrelor (180 mg single oral dose) by 73% and 86%, respectively, and decreased the AUC of its active metabolite by 46%.<sup>1,2,3</sup> Maximal platelet aggregation inhibition and platelet aggregation inhibition in the 12 hours after ticagrelor dosing were unaffected by rifampin, but platelet aggregation inhibition in the 24 hours after ticagrelor dosing was reduced by an average of 27%.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A-mediated ticagrelor metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. <i>Eur J Clin Pharmacol</i>. 2013;69(4):877-883. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23093043\">[PubMed 23093043]</a></p>\n<p>2. Brilinta (ticagrelor) [prescribing information]. Wilmington, DE: AstraZeneca LP; March 2015.</p>\n<p>3. Brilinta (ticagrelor) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6339":"<p><b>Title</b> Methylene Blue / BusPIRone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> BusPIRone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of buspirone for a period of 2 weeks prior to administration of methylene blue. In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue buspirone immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last buspirone dose, or 24 hours after the last dose of methylene blue, whichever comes first. Buspirone treatment may be resumed 24 hours after the last dose of methylene blue.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management, and expanded the warning to include other serotonergic drugs such as bupropion, buspirone, maprotiline, and MAO inhibitors.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6340":"<p><b>Title</b> Methylene Blue / Monoamine Oxidase Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of monoamine oxidase inhibitors (MAOIs) for a period of 2 weeks prior to administration of methylene blue. In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue the MAOI immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last MAOI dose, or 24 hours after the last dose of methylene blue, whichever comes first. MAOI treatment may be resumed 24 hours after the last dose of methylene blue.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management, and expanded the warning to include other serotonergic drugs such as bupropion, buspirone, maprotiline, and MAO inhibitors.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6341":"<p><b>Title</b> Methylene Blue / Maprotiline</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Maprotiline may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of maprotiline for a period of 2 weeks prior to administration of methylene blue. In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue maprotiline immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last maprotiline dose, or 24 hours after the last dose of methylene blue, whichever comes first. Maprotiline treatment may be resumed 24 hours after the last dose of methylene blue.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management, and expanded the warning to include other serotonergic drugs such as bupropion, buspirone, maprotiline, and MAO inhibitors.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6342":"<p><b>Title</b> Porfimer / Photosensitizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients more closely for evidence of photosensitivity when porfimer is used with other photosensitizing agents.</p>\n<div>\n <p><b>Photosensitizing Agents Interacting Members</b> Aceclofenac, Acemetacin, Acitretin, Adapalene, Afatinib, Afloqualone, Alitretinoin (Systemic), Alitretinoin (Topical), Aminolevulinic Acid (Systemic), Aminolevulinic Acid (Topical), Amiodarone, Bendroflumethiazide, Bexarotene (Systemic), Bexarotene (Topical), Bicalutamide, Calcitriol (Topical), Celecoxib, Chlorothiazide, ChlorproMAZINE, ChlorproPAMIDE, Chlorthalidone, Ciprofloxacin (Systemic), Cobimetinib, Cyclopenthiazide, Demeclocycline, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Dong Quai, Doxycycline, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, FluPHENAZine, Flurbiprofen (Systemic), Gemifloxacin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Griseofulvin, HydroCHLOROthiazide, Hydroflumethiazide, Ibuprofen, Ibuprofen (Topical), Indapamide, Indomethacin, ISOtretinoin (Systemic), Isotretinoin (Topical), Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Lornoxicam, Loxoprofen, Lymecycline, Meclofenamate, Mefenamic Acid, Meloxicam, Methotrimeprazine, Methyclothiazide, MetOLazone, Minocycline, Morniflumate, Moxifloxacin (Systemic), Nabumetone, Nadifloxacin, Nalidixic Acid, Naproxen, Nimesulide, Norfloxacin, Ofloxacin (Systemic), Oxaprozin, Oxytetracycline, Panitumumab, Parecoxib, Pelubiprofen, Periciazine, Perphenazine, Phenylbutazone, Pipemidic Acid, Pipotiazine, Pirfenidone, Piroxicam (Systemic), Piroxicam (Topical), Porfimer, Prochlorperazine, Promazine, Propyphenazone, Simeprevir, Sparfloxacin, St John's Wort, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Sulindac, Talniflumate, Tenoxicam, Tetracycline (Systemic), Thioridazine, Tiaprofenic Acid, TOLAZamide, TOLBUTamide, Tolfenamic Acid, Tolmetin, Tretinoin (Systemic), Tretinoin (Topical), Trifluoperazine, Vemurafenib, Verteporfin, Voriconazole, Xipamide, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Porfimer prescribing information cautions that concurrent use with other photosensitizing agents may increase the risk for a photosensitivity reaction.<sup>1</sup> The individual drugs listed herein as being photosensitizing agents are included primarily based on the findings of published analyses/reviews and individual drug labeling information.<sup>2,3,4</sup><br><br>The proposed mechanism for this potential interaction is additive phototoxicity between porfimer and other photosensitizing agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Photofrin</i> (porfimer) [prescribing information]. Bannockburn, IL: Pinnacle Biologics, Inc., 06/2011.</p>\n<p>2. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. <i>Br J Clin Pharmacol</i>. 1999;48(6):839-846. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594488\">[PubMed 10594488]</a></p>\n<p>3. Lankerani L, Baron ED. Photosensitivity to exogenous agents. <i>J Cutan Med Surg</i>. 2004;8(6):424-431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15988550\">[PubMed 15988550]</a></p>\n<p>4. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. <i>Drug Saf</i>. 2011;34(10):821-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21879777\">[PubMed 21879777]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6344":"<p><b>Title</b> Varenicline / Histamine H2 Receptor Antagonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: Canadian product monograph recommends avoiding use with cimetidine or ranitidine in patients with severe renal impairment (creatinine clearance &lt;30 mL/min)</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. Varenicline U.S. prescribing information recommends a dose reduction in patients with severe renal impairment regardless of cimetidine use, but does not prohibit use in patients receiving concomitant cimetidine or other H2-antagonists. Varenicline Canadian product monograph recommends avoiding concomitant use with cimetidine or ranitidine in patients with severe renal impairment (estimated creatinine clearance &lt;30 mL/min).</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine*, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Coadministration of cimetidine (300 mg QID) with varenicline (2 mg single dose) to 12 smokers increased varenicline systemic exposure 29%.<sup>1</sup> The mechanism for the observed interaction is thought to be a reduction in varenicline renal clearance. Varenicline undergoes renal elimination primarily by glomerular filtration and by active tubular secretion. In vitro studies have demonstrated that organic cation transporter (OCT2) may mediate varenicline renal tubular secretion (following uptake into renal tubular cells via OCT2, varenicline undergoes renal tubular secretion).<sup>1</sup> Cimetidine inhibits OCT2. Some in vitro studies suggest that ranitidine and famotidine may also inhibit OCT2,<sup>2</sup> while data regarding nizatidine is lacking. <br><br>Varenicline U.S. prescribing information recommends a dose reduction in patients with severe renal impairment regardless of cimetidine use, but does not prohibit use in patients receiving concomitant cimetidine or other H2-antagonists. In contrast, the Canadian product monograph recommends avoiding concomitant use with cimetidine and ranitidine in patients with severe renal impairment (estimated creatinine clearance &lt;30 mL/min).<sup>3</sup> Considering varenicline systemic exposure is increased approximately 2-fold in patients with severe renal impairment, it would seem prudent to consider monitoring for increased varenicline adverse effects in this patient population, particularly with concomitant use of drugs (e.g., cimetidine) that may impair its clearance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Chantix (varenicline). New York, NY: Pfizer Inc., July 2011.</p>\n<p>2. Bourdet DL, Pritchard JB, and Thakker DR, “Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3),” <i>J Pharmacol Exp Ther</i>, 2005, 315(3):1288-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141367\">[PubMed 16141367]</a></p>\n<p>3. Product monograph. Champix (varenicline). Kirkland, Quebec: Pfizer Canada Inc., December 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6348":"<p><b>Title</b> Esomeprazole / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Esomeprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of rifampin and esomeprazole, due to a possible risk of reduced esomeprazole therapeutic effects.</p> \n<p><b>Discussion</b> In a clinical study of 24 healthy volunteers, administration of rifampin (20, 100, or 500 mg daily for 14 days) decreased the omeprazole/5-hydroxyomeprazole ratio (a marker of CYP2C19 function) and the omeprazole/omeprazole sulfone metabolic ratio (a marker of CYP3A4 function) in a dose dependent manner.<sup>1</sup> These results suggest rifampin induction of CYP2C19 and CYP3A4 mediated omeprazole metabolism. Additionally, in a clinical study of 12 healthy volunteers, St John's wort (a CYP3A4 inducer) decreased omeprazole (20 mg single oral dose) maximum concentration and AUC by 38% and 38%, respectively in subjects with CYP2C19*2/*2 or *3 genotype (associated with “poor metabolizer” phenotype) and by 50% and 44%, respectively, in subjects with CYP2C19*1/*1 genotype (associated with “extensive metabolizer” phenotype).<sup>2,3</sup> Stereospecific pharmacokinetic variables were not calculated in either study for determination of the effect on esomeprazole (the S-isomer of omeprazole).<br><br>The likely primary mechanism of this interaction is rifampin induction of CYP3A4 and CYP2C19 mediated omeprazole metabolism. Esomeprazole prescribing information recommends avoiding coadministration with rifampin due to a possible risk of diminished esomeprazole therapeutic effects.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kanebratt KP, Diczfalusy U, Backstroo T, et al, “Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4Beta-Hydroxycholesterol,” <i>Clin Pharmacol Ther</i>, 2008, 84(5):589-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650803\">[PubMed 18650803]</a></p>\n<p>2. Wang LS, Zhou G, Zhu B, et al, “St John's Wort Induces Both Cytochrome P450 3A4-Catalyzed Sulfoxidation and 2C19-Dependent Hydroxylation of Omeprazole,” <i>Clin Pharmacol Ther</i>, 2004, 75(3):191-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15001970\">[PubMed 15001970]</a></p>\n<p>3. Prescribing information. Nexium (esomeprazole). Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6349":"<p><b>Title</b> Esomeprazole / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Esomeprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of rifampin and esomeprazole, due to a possible risk of diminished esomeprazole therapeutic effects.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, coadministration of St John's wort extract (300 mg tablet orally daily for 14 days, containing 0.3% total hypericin and a minimum 4% hyperforin, Hypericum Buyers Club, Inc, Los Angeles, CA) decreased omeprazole (20 mg single oral dose) maximum concentration and AUC by 38% and 38%, respectively in subjects with CYP2C19*2/*2 or *3 genotype (associated with “poor metabolizer” phenotype) and by 50% and 44%, respectively, in subjects with CYP2C19*1/*1 genotype (associated with “extensive metabolizer” phenotype).<sup>1,2</sup> Stereospecific pharmacokinetic variables were not calculated for determination of the effect on esomeprazole (the S-isomer of omeprazole).<br><br>The likely primary mechanism of this interaction is St John's wort induction of CYP3A4 mediated omeprazole metabolism, based on a 2.5 fold increase in omeprazole sulfone (a product of CYP3A4 mediated metabolism) AUC. By comparison, 5-hydroxyomeprazole (a product of CYP2C19 mediated metabolism) increased by only 35% in CYP2C19*1/*1 carriers. Esomeprazole prescribing information recommends avoiding coadministration with St John's wort due to a possible risk of diminished esomeprazole therapeutic effects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wang LS, Zhou G, Zhu B, et al, “St John's Wort Induces Both Cytochrome P450 3A4-Catalyzed Sulfoxidation and 2C19-Dependent Hydroxylation of Omeprazole,” <i>Clin Pharmacol Ther</i>, 2004, 75(3):191-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15001970\">[PubMed 15001970]</a></p>\n<p>2. Prescribing information. Nexium (esomeprazole). Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6350":"<p><b>Title</b> Omeprazole / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Omeprazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of St John's wort and omeprazole, due to a possible risk of diminished omeprazole therapeutic effects.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, coadministration of St John's wort extract (300 mg tablet orally daily for 14 days, containing 0.3% total hypericin and a minimum 4% hyperforin, Hypericum Buyers Club, Inc, Los Angeles, CA) decreased omeprazole (20 mg single oral dose) maximum concentration and AUC by 38% and 38%, respectively in subjects with CYP2C19*2/*2 or *3 genotype (associated with “poor metabolizer” phenotype) and by 50% and 44%, respectively, in subjects with CYP2C19*1/*1 genotype (associated with “extensive metabolizer” phenotype).<sup>1,2</sup><br><br>The likely primary mechanism of this interaction is St John's wort induction of CYP3A4 mediated omeprazole metabolism, based on a 2.5 fold increase in omeprazole sulfone (a product of CYP3A4 mediated metabolism) AUC. By comparison, 5-hydroxyomeprazole (a product of CYP2C19 mediated metabolism) increased by only 35% in CYP2C19*1/*1 carriers. Omeprazole prescribing information recommends avoiding coadministration with St John's wort due to a possible risk of diminished omeprazole therapeutic effects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wang LS, Zhou G, Zhu B, et al, “St John's Wort Induces Both Cytochrome P450 3A4-Catalyzed Sulfoxidation and 2C19-Dependent Hydroxylation of Omeprazole,” <i>Clin Pharmacol Ther</i>, 2004, 75(3):191-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15001970\">[PubMed 15001970]</a></p>\n<p>2. Prescribing information. Prilosec (omeprazole). Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6351":"<p><b>Title</b> Omeprazole / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Omeprazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of rifampin and omeprazole, due to a possible risk of reduced omeprazole therapeutic effects.</p> \n<p><b>Discussion</b> In a clinical study of 24 healthy volunteers, administration of rifampin (20, 100, or 500 mg daily for 14 days) decreased the omeprazole/5-hydroxyomeprazole ratio (a marker of CYP2C19 function) and the omeprazole/omeprazole sulfone metabolic ratio (a marker of CYP3A4 function) in a dose dependent manner.<sup>1</sup> These results suggest rifampin induction of CYP2C19 and CYP3A4 mediated omeprazole metabolism. Additionally, in a clinical study of 12 healthy volunteers, St John's wort (a CYP3A4 inducer) decreased omeprazole (20 mg single oral dose) maximum concentration and AUC by 38% and 38%, respectively in subjects with CYP2C19*2/*2 or *3 genotype (associated with “poor metabolizer” phenotype) and by 50% and 44%, respectively, in subjects with CYP2C19*1/*1 genotype (associated with “extensive metabolizer” phenotype).<sup>2,3</sup><br><br>The likely primary mechanism of this interaction is rifampin induction of CYP3A4 and CYP2C19 mediated omeprazole metabolism. Omeprazole prescribing information recommends avoiding coadministration with rifampin due to a possible risk of diminished omeprazole therapeutic effects.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kanebratt KP, Diczfalusy U, Backstroo T, et al, “Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4Beta-Hydroxycholesterol,” <i>Clin Pharmacol Ther</i>, 2008, 84(5):589-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650803\">[PubMed 18650803]</a></p>\n<p>2. Wang LS, Zhou G, Zhu B, et al, “St John's Wort Induces Both Cytochrome P450 3A4-Catalyzed Sulfoxidation and 2C19-Dependent Hydroxylation of Omeprazole,” <i>Clin Pharmacol Ther</i>, 2004, 75(3):191-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15001970\">[PubMed 15001970]</a></p>\n<p>3. Prescribing information. Prilosec (omeprazole). Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6352":"<p><b>Title</b> DOCEtaxel / Dronedarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dronedarone may increase the serum concentration of DOCEtaxel. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid this combination whenever possible. If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.).</p> \n<p><b>Discussion</b> A case report describes a 79-year-old man receiving docetaxel and dronedarone whose death was attributed to a docetaxel overdose.<sup>1</sup> Measurable docetaxel serum concentrations remained even 22 days from the end of the chemotherapy regimen.<br><br>The proposed mechanism for this interaction is dronedarone-mediated inhibition of both CYP3A4 and p-glycoprotein. Dronedarone is a moderate inhibitor of CYP3A4 and an inhibitor of p-glycoprotein, both of which appear to be involved in the metabolism and distribution/elimination of docetaxel.<sup>2,3</sup> Of note, combined inhibition of CYP3A4 and p-glycoprotein in an animal study resulted in particularly dramatic increase in docetaxel concentrations (70-fold), much beyond what was observed with inhibition of CYP3A4 or p-glycoprotein alone (12-fold and 3-fold increases, respectively).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vodovar D, Arnaout M, Mongardon N, et al, “Severe Docetaxel Overdose Induced by Pharmacokinetic Interaction With Dronedarone,” <i>Journal of Clinical Oncology</i>, 2011, 29:1-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21730272\">[PubMed 21730272]</a></p>\n<p>2. Prescribing information. Multaq (dronedarone). Bridgewater, NJ: sanofi-aventis U.S. LLC, 06/2011.</p>\n<p>3. van Waterschoot RA, Lagas JS, Wagenaar E, et al, “Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity,” <i>Cancer Res</i>, 2009, 69(23):8996-9002. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19920203\">[PubMed 19920203]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6355":"<p><b>Title</b> Sodium Polystyrene Sulfonate / Meloxicam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b> (Suspension): This interaction is only expected with Mobic (meloxicam) oral suspension, which contains sorbitol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Meloxicam may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) with meloxicam oral suspension, because sorbitol in the suspension may increase risk of intestinal necrosis.</p> \n<p><b>Discussion</b> Retrospective studies and case reports have linked rectal and/or oral use of sodium polystyrene sulfonate (SPS) preparations with sorbitol to severe upper and lower gastrointestinal (GI) tract adverse events.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16</sup> Prescribing information for SPS recommends that concomitant treatment with sorbitol should be avoided.<sup>17</sup><br><br>The exact mechanism of this interaction is unclear. SPS and related compounds used without sorbitol have been reported in relatively few cases of severe gastrointestinal complications.<sup>18,19</sup> Additionally, in animal studies involving uremic and nonuremic rats, administration of sorbitol-containing enemas (with or without SPS) was associated with colonic necrosis while administration of saline or SPS (without sorbitol) was not associated with any significant pathologic changes.<sup>20</sup> In addition to predisposing risk factors for adverse GI events (e.g. renal insufficiency, intestinal surgery), possible mechanisms suggested include vasospasm in response to osmotic intestinal mucosa injury due to sorbitol and inflammatory exacerbation due to increased prostaglandin levels.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McGowan CE, Saha S, Chu G, et al, “Intestinal Necrosis Due to Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol,” <i>South Med J,</i> 2009, 102(5):493-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19373153\">[PubMed 19373153]</a></p>\n<p>2. Rashid, A, Hamilton SR, “Necrosis of the Gastrointestinal Tract in Uremic Patients as a Result of Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol: An Underrecognized Condition,” <i>Am J Surg Pathol,</i> 1997, 21(1):60-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8990142\">[PubMed 8990142]</a></p>\n<p>3. Abraham SC, Bhagavan BS, Lee LA, et al, “Upper Gastrointestinal Tract Injury in Patients Receiving Kayexalate (Sodium Polystyrene Sulfonate) in Sorbitol,” <i>Am J Surg Pathol,</i> 2001, 25(5):637-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11342776\">[PubMed 11342776]</a></p>\n<p>4. Dardik A, Moesinger RC, Efron G, et al, “Acute Abdomen With Colonic Necrosis Induced by Kayexalate-Sorbitol,” <i>South Med J,</i> 2000, 93(5):511-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10832954\">[PubMed 10832954]</a></p>\n<p>5. Rogers FB and Li SC, “Acute Colonic Necrosis Associated with Sodium Polystyrene Sulfonate (Kayexalate) Enemas in a Critically Ill Patient: Case Report and Review of the Literature,” <i>J Trauma,</i> 2001, 51(2):395-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11493807\">[PubMed 11493807]</a></p>\n<p>6. Trottier V, Drolet S and Morcos MW, “Ileocolic Perforation Secondary to Sodium Polystyrene Sulfonate in Sorbitol Use: A Case Report,” <i>Can J Gastroenterol</i>, 2009, 23(10):689-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19826644\">[PubMed 19826644]</a></p>\n<p>7. Thomas A, James BR and Landsberg D, “Colonic Necrosis due to Oral Kayexalate in a Critically-Ill Patient,” <i>Am J Med Sci</i>, 2009, 337(4):305-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19365182\">[PubMed 19365182]</a></p>\n<p>8. Chlumska A, Boudova L, Pavlovsky M, et al, “Intestinal Necrosis Following Calcium Resonium-Sorbitol Administration in a Premature Uraemic Infant,” <i>Cesk Patol</i>, 2002, 38(4):169-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12629864\">[PubMed 12629864]</a></p>\n<p>9. Gardiner GW, “Kayexalate (Sodium Polystyrene Sulphonate) in Sorbitol Associated with Intestinal Necrosis in Uremic Patients,” <i>Can J Gastroenterol</i>, 1997, 11(7):573-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9395757\">[PubMed 9395757]</a></p>\n<p>10. Roy-Chaudhury P, Meisels IS, Freedman S, et al, “Combined Gastric and Ileocecal Toxicity (Serpiginous Ulcers) After Oral Kayexalate in Sorbital Therapy,” <i>Am J Kidney Dis</i>, 1997, 30(1):120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9214411\">[PubMed 9214411]</a></p>\n<p>11. Gerstman BB, Kirkman R and Platt R, “Intestinal Necrosis Associated with Postoperative Orally Administered Sodium Polystyrene Sulfonate in Sorbitol,” <i>Am J Kidney Dis</i>, 1992, 20(2):159-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1496969\">[PubMed 1496969]</a></p>\n<p>12. Scott TR, Graham SM and Schweitzer EJ, “Colonic Necrosis Following Sodium Polystyrene Sulfonate (Kayexalate)-Sorbitol Enema in a Renal Transplant Patient. Report of a Case and Review of the Literature,” <i>Dis Colon Rectum</i>, 1993, 36(6):607-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8500380\">[PubMed 8500380]</a></p>\n<p>13. Wootton FT, Rhodes DF, Lee WM, et al, “Colonic Necrosis with Kayexalate-Sorbitol Enemas After Renal Transplantation,” <i>Ann Intern Med</i>, 1989, 111(11):947-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2817643\">[PubMed 2817643]</a></p>\n<p>14. Milley JR and Jung AL, “Hematochezia Associated with the Use of Hypertonic Sodium Polystyrene Sulfonate Enemas in Premature Infants,” <i>J Perinatol</i>, 1995, 15(2):139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7595773\">[PubMed 7595773]</a></p>\n<p>15. Bennett LN, Myers TF and Lambert GH, “Cecal Perforation Associated with Sodium Polystyrene Sulfonate-Sorbitol Enemas in a 650 Gram Infant with Hyperkalemia,” <i>Am J Perinatol</i>, 1996, 13(3):167-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8688109\">[PubMed 8688109]</a></p>\n<p>16. Lillemoe KD, Romolo JL, Hamilton SR, et al, “Intestinal Necrosis Due to Sodium Polystyrene (Kayexalate) in Sorbitol Enemas: Clinical and Experimental Support For The Hypothesis,” <i>Surgery,</i> 1987, 101(3):267-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3824154\">[PubMed 3824154]</a></p>\n<p>17. Prescribing information. Kayexalate (sodium polystyrene sulfonate). Bridewater, NJ: Sanofi-Aventis U.S. LLC, September 2009.</p>\n<p>18. Rugolotto S, Gruber M, Solano PD, et al, “Necrotizing Enterocolitis in a 850 Gram Infant Receiving Sorbitol-Free Sodium Polystyrene Sulfonate (Kayexalate): Clinical and Histopathologic Findings,” <i>J Perinatol</i>, 2007, 27(4):247-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17377608\">[PubMed 17377608]</a></p>\n<p>19. Joo M, Bae WK, Kim NH, et al, “Colonic Mucosal Necrosis Following Administration of Calcium Polystryrene Sulfonate (Kalimate) in a Uremic Patient,” <i>J Korean Med Sci</i>, 2009, 24(6):1207-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19949685\">[PubMed 19949685]</a></p>\n<p>20. Lillemoe KD, Romolo JL, Hamilton SR, et al, “Intestinal Necrosis Due to Sodium Polystyrene (Kayexalate) in Sorbitol Enemas: Clinical and Experimental Support For The Hypothesis,” <i>Surgery,</i> 1987, 101(3):267-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3824154\">[PubMed 3824154]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6356":"<p><b>Title</b> Calcium Polystyrene Sulfonate / Meloxicam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b> (Suspension): This interaction is only expected with Mobic (meloxicam) oral suspension, which contains sorbitol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Meloxicam may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) with meloxicam oral suspension, because sorbitol in the suspension may increase risk of intestinal necrosis.</p> \n<p><b>Discussion</b> Retrospective studies and case reports have linked rectal and/or oral use of sodium polystyrene sulfonate (SPS) preparations with sorbitol to severe upper and lower gastrointestinal (GI) tract adverse events.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16</sup> Prescribing information for the related compound calcium polystyrene sulfonate (CPS) recommends that concomitant treatment with sorbitol should be avoided.<sup>17</sup><br><br>The exact mechanism of this interaction is unclear. SPS and CPS used without sorbitol have been reported in relatively few cases of severe gastrointestinal complications.<sup>18,19</sup> Additionally, in animal studies involving uremic and nonuremic rats, administration of sorbitol-containing enemas (with or without SPS) was associated with colonic necrosis while administration of saline or SPS (without sorbitol) was not associated with any significant pathologic changes.<sup>20</sup> In addition to predisposing risk factors for adverse GI events (e.g. renal insufficiency, intestinal surgery), possible mechanisms suggested include vasospasm in response to osmotic intestinal mucosa injury due to sorbitol and inflammatory exacerbation due to increased prostaglandin levels.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McGowan CE, Saha S, Chu G, et al, “Intestinal Necrosis Due to Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol,” <i>South Med J,</i> 2009, 102(5):493-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19373153\">[PubMed 19373153]</a></p>\n<p>2. Rashid, A, Hamilton SR, “Necrosis of the Gastrointestinal Tract in Uremic Patients as a Result of Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol: An Underrecognized Condition,” <i>Am J Surg Pathol,</i> 1997, 21(1):60-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8990142\">[PubMed 8990142]</a></p>\n<p>3. Abraham SC, Bhagavan BS, Lee LA, et al, “Upper Gastrointestinal Tract Injury in Patients Receiving Kayexalate (Sodium Polystyrene Sulfonate) in Sorbitol,” <i>Am J Surg Pathol,</i> 2001, 25(5):637-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11342776\">[PubMed 11342776]</a></p>\n<p>4. Dardik A, Moesinger RC, Efron G, et al, “Acute Abdomen With Colonic Necrosis Induced by Kayexalate-Sorbitol,” <i>South Med J,</i> 2000, 93(5):511-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10832954\">[PubMed 10832954]</a></p>\n<p>5. Rogers FB and Li SC, “Acute Colonic Necrosis Associated with Sodium Polystyrene Sulfonate (Kayexalate) Enemas in a Critically Ill Patient: Case Report and Review of the Literature,” <i>J Trauma,</i> 2001, 51(2):395-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11493807\">[PubMed 11493807]</a></p>\n<p>6. Trottier V, Drolet S and Morcos MW, “Ileocolic Perforation Secondary to Sodium Polystyrene Sulfonate in Sorbitol Use: A Case Report,” <i>Can J Gastroenterol</i>, 2009, 23(10):689-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19826644\">[PubMed 19826644]</a></p>\n<p>7. Thomas A, James BR and Landsberg D, “Colonic Necrosis due to Oral Kayexalate in a Critically-Ill Patient,” <i>Am J Med Sci</i>, 2009, 337(4):305-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19365182\">[PubMed 19365182]</a></p>\n<p>8. Chlumska A, Boudova L, Pavlovsky M, et al, “Intestinal Necrosis Following Calcium Resonium-Sorbitol Administration in a Premature Uraemic Infant,” <i>Cesk Patol</i>, 2002, 38(4):169-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12629864\">[PubMed 12629864]</a></p>\n<p>9. Gardiner GW, “Kayexalate (Sodium Polystyrene Sulphonate) in Sorbitol Associated with Intestinal Necrosis in Uremic Patients,” <i>Can J Gastroenterol</i>, 1997, 11(7):573-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9395757\">[PubMed 9395757]</a></p>\n<p>10. Roy-Chaudhury P, Meisels IS, Freedman S, et al, “Combined Gastric and Ileocecal Toxicity (Serpiginous Ulcers) After Oral Kayexalate in Sorbital Therapy,” <i>Am J Kidney Dis</i>, 1997, 30(1):120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9214411\">[PubMed 9214411]</a></p>\n<p>11. Gerstman BB, Kirkman R and Platt R, “Intestinal Necrosis Associated with Postoperative Orally Administered Sodium Polystyrene Sulfonate in Sorbitol,” <i>Am J Kidney Dis</i>, 1992, 20(2):159-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1496969\">[PubMed 1496969]</a></p>\n<p>12. Scott TR, Graham SM and Schweitzer EJ, “Colonic Necrosis Following Sodium Polystyrene Sulfonate (Kayexalate)-Sorbitol Enema in a Renal Transplant Patient. Report of a Case and Review of the Literature,” <i>Dis Colon Rectum</i>, 1993, 36(6):607-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8500380\">[PubMed 8500380]</a></p>\n<p>13. Wootton FT, Rhodes DF, Lee WM, et al, “Colonic Necrosis with Kayexalate-Sorbitol Enemas After Renal Transplantation,” <i>Ann Intern Med</i>, 1989, 111(11):947-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2817643\">[PubMed 2817643]</a></p>\n<p>14. Milley JR and Jung AL, “Hematochezia Associated with the Use of Hypertonic Sodium Polystyrene Sulfonate Enemas in Premature Infants,” <i>J Perinatol</i>, 1995, 15(2):139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7595773\">[PubMed 7595773]</a></p>\n<p>15. Bennett LN, Myers TF and Lambert GH, “Cecal Perforation Associated with Sodium Polystyrene Sulfonate-Sorbitol Enemas in a 650 Gram Infant with Hyperkalemia,” <i>Am J Perinatol</i>, 1996, 13(3):167-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8688109\">[PubMed 8688109]</a></p>\n<p>16. Lillemoe KD, Romolo JL, Hamilton SR, et al, “Intestinal Necrosis Due to Sodium Polystyrene (Kayexalate) in Sorbitol Enemas: Clinical and Experimental Support For The Hypothesis,” <i>Surgery,</i> 1987, 101(3):267-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3824154\">[PubMed 3824154]</a></p>\n<p>17. Prescribing information. Resonium Calcium (calcium polystyrene sulfonate). Laval, Quebec: Sanofi-Aventis Canada Inc., April 2006.</p>\n<p>18. Rugolotto S, Gruber M, Solano PD, et al, “Necrotizing Enterocolitis in a 850 Gram Infant Receiving Sorbitol-Free Sodium Polystyrene Sulfonate (Kayexalate): Clinical and Histopathologic Findings,” <i>J Perinatol</i>, 2007, 27(4):247-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17377608\">[PubMed 17377608]</a></p>\n<p>19. Joo M, Bae WK, Kim NH, et al, “Colonic Mucosal Necrosis Following Administration of Calcium Polystryrene Sulfonate (Kalimate) in a Uremic Patient,” <i>J Korean Med Sci</i>, 2009, 24(6):1207-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19949685\">[PubMed 19949685]</a></p>\n<p>20. Lillemoe KD, Romolo JL, Hamilton SR, et al, “Intestinal Necrosis Due to Sodium Polystyrene (Kayexalate) in Sorbitol Enemas: Clinical and Experimental Support For The Hypothesis,” <i>Surgery,</i> 1987, 101(3):267-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3824154\">[PubMed 3824154]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6357":"<p><b>Title</b> Simvastatin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid strong CYP3A4 inhibitors in combination with simvastatin, due to a risk of muscle toxicity (including rhabdomyolysis) with elevated simvastatin concentrations. Simvastatin US prescribing information specifically lists this as a contraindication. If treatment with clarithromycin, telithromycin, itraconazole, ketoconazole, or posaconazole is needed, simvastatin should be suspended during the course of treatment. Alternative HMG-CoA reductase inhibitors that are less likely to be significantly affected by CYP3A4 inhibition include fluvastatin, rosuvastatin, pitavastatin, and pravastatin.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Combinations of simvastatin with various strong CYP3A4 inhibitors (atazanavir, clarithromycin, ketoconazole, nefazodone, nelfinavir, ritonavir) have been associated with cases of severe, sometimes fatal muscle toxicity.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13</sup> Coadministration of strong CYP3A4 inhibitors with simvastatin in published clinical studies increased the AUC of simvastatin, by approximately 3-fold with imatinib, 6-fold with nelfinavir, 10-fold with clarithromycin, 13-fold with ketoconazole, and 31.6-fold with saquinavir/ritonavir.<sup>14,15,16,17,18</sup> The AUC of simvastatin acid was calculated in two of these studies, and increased by approximately 2-fold with imatinib and 12-fold with clarithromycin.<sup>16,17</sup><br><br>The likely primary mechanism of this interaction is inhibition of CYP3A4 mediated simvastatin metabolism, leading to increases in simvastatin and simvastatin acid concentrations and associated toxicities. Due to the potential severity of this interaction, simvastatin prescribing information lists coadministration with strong CYP3A4 inhibitors as contraindicated.<sup>19</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jacobson RH, Wang P, and Glueck CJ, “Myositis and Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Nefazodone,” <i>JAMA</i>, 1997, 277(4):296-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9002485\">[PubMed 9002485]</a></p>\n<p>2. Gilad R and Lampl Y, “Rhabdomyolysis Induced by Simvastatin and Ketoconazole Treatment,” <i>Clin Neuropharmacol</i>, 1999, 22(5):295-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516882\">[PubMed 10516882]</a></p>\n<p>3. Cheng CH, Miller C, Lowe C, et al, “Rhabdomyolysis Due to Probable Interaction Between Simvastatin and Ritonavir,” <i>Am J Health Syst Pharm</i>, 2002, 59(8):728-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11977859\">[PubMed 11977859]</a></p>\n<p>4. Thompson M and Samuels S, “Rhabdomyolysis With Simvastatin and Nefazodone,” <i>Am J Psychiatry</i>, 2002, 159(9):1607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12202291\">[PubMed 12202291]</a></p>\n<p>5. Hare CB, Vu MP, Grunfeld C, et al, “Simvastatin-Nelfinavir Interaction Implicated in Rhabdomyolysis and Death,” <i>Clin Infect Dis</i>, 2002, 35(10):e111-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12410494\">[PubMed 12410494]</a></p>\n<p>6. Itakura H, Vaughn D, Haller DG, et al, “Rhabdomyolysis From Cytochrome P-450 Interaction of Ketoconazole and Simvastatin in Prostate Cancer,” <i>J Urol</i>, 2003, 169(2):613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12544321\">[PubMed 12544321]</a></p>\n<p>7. Skrabal MZ, Stading JA and Monaghan MS, “Rhabdomyolysis Associated With Simvastatin-Nefazodone Therapy,” <i>South Med J</i>, 2003, 96(10):1034-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14570351\">[PubMed 14570351]</a></p>\n<p>8. Kahri AJ, Valkonen MM, Vuoristo MK, et al, “Rhabdomyolysis Associated With Concomitant Use of Simvastatin and Clarithromycin,” <i>Ann Pharmacother</i>, 2004, 38(4):719. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14966253\">[PubMed 14966253]</a></p>\n<p>9. Trieu J, Emmett L, Perera C, et al, “Rhabdomyolysis Resulting From Interaction of Simvastatin and Clarithromycin Demonstrated by Tc-99m MDP Scintigraphy,” <i>Clin Nucl Med</i>, 2004, 29(12):803-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15545884\">[PubMed 15545884]</a></p>\n<p>10. Chouhan UM, Chakrabarti S and Millward LJ, “Simvastatin Interaction With Clarithromycin and Amiodarone Causing Myositis,” <i>Ann Pharmacother</i>, 2005, 39(10):1760-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16159992\">[PubMed 16159992]</a></p>\n<p>11. Molden E and Andersson KS, “Simvastatin-Associated Rhabdomyolysis After Coadministration of Macrolide Antibiotics in Two Patients,” <i>Pharmacotherapy</i>, 2007, 27(4):603-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17381388\">[PubMed 17381388]</a></p>\n<p>12. Schmidt GA, Hoehns JD, Purcell JL, et al, “Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir,” <i>J Am Board Fam Med</i>, 2007, 20(4):411-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17615423\">[PubMed 17615423]</a></p>\n<p>13. Wagner J, Suessmair C, and Pfister HW, “Rhabdomyolysis Caused by Co-Medication With Simvastatin and Clarithromycin,” <i>J Neurol</i>, 2009, 256(7):1182-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19252767\">[PubMed 19252767]</a></p>\n<p>14. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al, “Pharmacokinetic Interactions Between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin,” <i>Antimicrob Agents Chemother</i>, 2001, 45(12):3445-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11709322\">[PubMed 11709322]</a></p>\n<p>15. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al, “Pharmacokinetic Interactions Between Protease Inhibitors and Statins in HIV Seronegative Volunteers: ACTG Study A5047,” <i>AIDS</i>, 2002, 16(4):569-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11873000\">[PubMed 11873000]</a></p>\n<p>16. O'Brien SG, Meinhardt P, Bond E, et al, “Effects of Imatinib Mesylate (STI571, Glivec) on the Pharmacokinetics of Simvastatin, a Cytochrome P450 3A4 Substrate, in Patients With Chronic Myeloid Leukaemia,” <i>Br J Cancer</i>, 2003, 89(10):1855-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14612892\">[PubMed 14612892]</a></p>\n<p>17. Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered With Cytochrome P450 Inhibitors,” <i>Am J Cardiol</i>, 2004, 94(9):1140-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15518608\">[PubMed 15518608]</a></p>\n<p>18. Chung E, Nafziger AN, Kazierad DJ, et al, “Comparison of Midazolam and Simvastatin as Cytochrome P450 3A Probes,” <i>Clin Pharmacol Ther</i>, 2006, 79(4):350-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16580903\">[PubMed 16580903]</a></p>\n<p>19. Prescribing information. Zocor (simvastatin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 6/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6359":"<p><b>Title</b> Lovastatin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid strong CYP3A4 inhibitors in combination with lovastatin, due to a risk of muscle toxicity (including rhabdomyolysis) with elevated lovastatin concentrations. Lovastatin US prescribing information specifically lists this as a contraindication. Alternative HMG-CoA reductase inhibitors that are less likely to be significantly affected by CYP3A4 inhibition include fluvastatin, rosuvastatin, pitavastatin, and pravastatin.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole*, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Combinations of lovastatin with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) have been associated with cases of severe muscle toxicity.<sup>1,2,3</sup> In clinical studies of healthy volunteers, coadministration of the strong CYP3A4 inhibitor itraconazole (100-200 mg daily for 4 days) with lovastatin (40 mg single dose) increased the average maximum concentrations and AUCs of lovastatin and lovastatin acid by greater than 10 fold each (some by greater than 20 fold).<sup>4,5</sup><br><br>The likely primary mechanism of this interaction is inhibition of CYP3A4 mediated lovastatin metabolism, leading to increases in lovastatin concentrations and associated toxicities. Due to the potential severity of this interaction, lovastatin prescribing information states that coadministration with strong CYP3A4 inhibitors is contraindicated.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8): 859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>2. Landesman KA, Stozek M and Freeman NJ, “Rhabdomyolysis Associated With the Combined Use of Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors With Gemfibrozil and Macrolide Antibiotics,” <i>Conn Med</i>, 1999, 63(8):455-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10500341\">[PubMed 10500341]</a></p>\n<p>3. Stein CA, Goel S and Ghavamian R, “Hepatitis and Rhabdomyolysis in a Patient With Hormone Refractory Prostate Cancer on Ketoconazole and Concurrent Lovastatin Therapy,” <i>Invest New Drugs</i>, 2007, 25(3):277-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17216557\">[PubMed 17216557]</a></p>\n<p>4. Kivisto KT, Kantola T and Neuvonen PJ, “Different Effects of Itraconazole on the Pharmacokinetics of Fluvastatin and Lovastatin,” <i>Br J Clin Pharmacol</i>, 1998, 46(1):49-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9690949\">[PubMed 9690949]</a></p>\n<p>5. Neuvonen PJ and Jalava KM, “Itraconazole Drastically Increases Plasma Concentrations of Lovastatin and Lovastatin Acid,” <i>Clin Pharmacol Ther</i>, 1996, 60(1):54-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8689812\">[PubMed 8689812]</a></p>\n<p>6. Prescribing information. Mevacor (lovastatin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 2/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6361":"<p><b>Title</b> PARoxetine / Pravastatin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pravastatin may enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider more regular monitoring of blood glucose concentrations in patients using this combination. Patients with diabetes or impaired glucose tolerance may be at particularly high risk for a clinically relevant interaction. Monitoring for decreased kidney function may also be warranted in patients receiving both pravastatin and paroxetine.</p> \n<p><b>Discussion</b> In two separate retrospective data set reviews concerning patients initiating paroxetine, pravastatin, or both, use of the combination was found to significantly increase blood glucose.<sup>1,2</sup> According to one review, in nondiabetic patients, the combination was associated with greater increases in blood glucose concentrations from baseline when compared with either drug alone (an increase of 18.5 mg/dL with the combination, compared with a decrease of 3.3 mg/dL with paroxetine alone and no change with pravastatin alone).<sup>1</sup> Results were more pronounced in diabetic patients (an increase of 48.1 mg/dL with the combination, compared with a decrease of 3.9 mg/dL with paroxetine alone and no change with pravastatin alone). Preliminary data from mice treated with pravastatin, paroxetine, or their combination also appear to support an interaction.<sup>1</sup> In another review, co-medication with paroxetine and pravastatin was also associated with an increase in blood glucose concentrations compared with pre-combination concentrations (132.1 mg/dL vs. 113.2 mg/dL).<sup>2</sup> This same review also noted laboratory evidence of diminished renal function (i.e., decrease in estimated glomerular filtration rate [GFR] and increase in blood carbon dioxide concentrations) following initiation of co-medication. It is, however, important to note that the number of patients receiving combined treatment was very small (n=12-39) for some of the analyses.<br><br>In contrast, a retrospective database study identified patients who received concomitant prescriptions for paroxetine and pravastatin (n=65) and compared glucose measurements with patients who were co-prescribed other statin and selective serotonin reuptake inhibitor (SSRI) pairs (n=2,084).<sup>3</sup> After adjustment for age, gender, diabetes, weight, and body mass index, there was no difference in fasting glucose, random glucose, or hemoglobin A1c measurements between groups.<sup>3</sup> The authors note that they were unable to reproduce the results of previous analyses. However, between group comparisons were only conducted on glucose measurements during the period of co-prescription. No comparisons of glucose control were made before and after prescription of the statin/SSRI pair. <br><br>The specific mechanism of this purported interaction is uncertain. Although further studies are needed, it is proposed that concomitant use of paroxetine and pravastatin may disrupt the balance of reactive oxygen species (ROS).<sup>2</sup> Hyperglycemia induced increase in ROS leading to decrease in GFR is a known pathophysiology for progressive kidney dysfunction.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tatonetti NP, Denny JC, Murphy SN, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. <i>Clin Pharmacol Ther</i>. 2011;90(1):133-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21613990\">[PubMed 21613990]</a></p>\n<p>2. An L, Ravindran PP, Renukunta S, Denduluri S. Co-medication of pravastatin and paroxetine- a categorical study. <i>J Clin Pharmacol</i>. 2013;53(11):1212-1219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23907716\">[PubMed 23907716]</a></p>\n<p>3. Orrico KB, Huynh MH, Olson CW. Comparison of glucose measurements in patients receiving concomitant paroxetine and pravastatin to other SSRI/statin combinations. <i>Ann Pharmacother</i>. 2014;48(9):1172-1176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24928102\">[PubMed 24928102]</a></p>\n<p>4. Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. <i>Pharmacol Ther</i>. 2010;128(1):61-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20600306\">[PubMed 20600306]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6362":"<p><b>Title</b> Thioridazine / Moclobemide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Moclobemide may increase the serum concentration of Thioridazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of moclobemide with thioridazine is contraindicated.</p> \n<p><b>Discussion</b> Moclobemide Canadian product monograph specifically contraindicates concomitant use with thioridazine.<sup>1</sup> Moclobemide may inhibit the CYP2D6 mediated metabolism of thioridazine, a drug whose use is associated with QTc prolongation. Increased thioridazine serum levels may potentiate the QTc interval prolongation and increase the risk of serious cardiac arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Manerix (moclobemide). Mississauga, Ontario: Hoffmann-LaRoche Limited, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6363":"<p><b>Title</b> Lapatinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of strong CYP3A4 inhibitors should generally be avoided during treatment with lapatinib. If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor (note: this dose adjustment recommendation is based on pharmacokinetic studies with lapatinib; its impact on safety and efficacy are unknown).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in lapatinib prescribing information, coadministration of ketoconazole (200 mg orally twice daily for 7 days) increased the maximum concentration (Cmax) and AUC of lapatinib (100 mg single oral dose) by 2.1 and 3.6 fold, respectively, in 22 healthy volunteers.<sup>1,2</sup> The mechanism of this interaction is likely at least twofold: 1) ketoconazole inhibition of CYP3A4 mediated lapatinib metabolism; and 2) ketoconazole inhibition of P-glycoprotein mediated lapatinib transport. Both of these mechanisms would be expected to increase lapatinib Cmax and AUC.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tykerb (lapatinib). Research Triangle Park, NC: GlaxoSmithKline, August 2011.</p>\n<p>2. Smith DA, Koch KM, Arya N, et al, “Effects of Ketoconazole and Carbamazepine on Lapatinib Pharmacokinetics in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2009, 67(4):421-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19371315\">[PubMed 19371315]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6364":"<p><b>Title</b> Lapatinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Lapatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving lapatinib should be advised to avoid consumption of grapefruit and grapefruit juice.</p> \n<p><b>Discussion</b> Lapatinib prescribing information recommends avoidance of grapefruit during treatment with lapatinib.<sup>1</sup> Grapefruit juice could theoretically decrease CYP3A4 mediated metabolism (primarily intestinal) and P-glycoprotein (P-gp) mediated transport, increasing systemic lapatinib concentrations. While data describing this specific interaction are lacking, in a clinical study of 22 healthy volunteers, coadministration of CYP3A4/P-gp inhibitor ketoconazole (200 mg orally twice daily for 7 days) increased the maximum concentration and AUC of lapatinib (100 mg single oral dose) by 2.1 and 3.6 fold, respectively.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tykerb (lapatinib). Research Triangle Park, NC: GlaxoSmithKline, August 2011.</p>\n<p>2. Smith DA, Koch KM, Arya N, et al, “Effects of Ketoconazole and Carbamazepine on Lapatinib Pharmacokinetics in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2009, 67(4):421-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19371315\">[PubMed 19371315]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6365":"<p><b>Title</b> Lapatinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of strong CYP3A4 inducers should generally be avoided during treatment with lapatinib. If an overlap in therapy cannot be avoided, consider titrating lapatinib dose gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor positive, HER2 positive breast cancer) based on tolerability (note: this dose adjustment recommendation is based on pharmacokinetic studies with lapatinib; its impact on safety and efficacy are unknown).</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine*, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in lapatinib prescribing information, coadministration of carbamazepine (titrated to 200 mg orally twice daily over 20 days) decreased the maximum concentration (Cmax) and AUC of lapatinib (250 mg single oral dose) by 59% and 72%, respectively, in 22 healthy volunteers.<sup>1,2</sup> The mechanism of this interaction is likely at least twofold: 1) carbamazepine induction of CYP3A4 mediated lapatinib metabolism; and 2) carbamazepine induction of P-glycoprotein mediated lapatinib transport. Both of these mechanisms would be expected to decrease lapatinib Cmax and AUC.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tykerb</i> (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2011.</p>\n<p>2. Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. <i>Br J Clin Pharmacol</i>. 2009;67(4):421-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19371315\">[PubMed 19371315]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6366":"<p><b>Title</b> Varenicline / Trimethoprim</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: Canadian product monograph recommends avoiding use with trimethoprim in patients with severe renal impairment (creatinine clearance &lt;30 mL/min)</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may increase the serum concentration of Varenicline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. Varenicline U.S. prescribing information recommends a dose reduction in patients with severe renal impairment regardless of trimethoprim use, but does not prohibit use in patients receiving concomitant trimethoprim. Varenicline Canadian product monograph recommends avoiding concomitant use with trimethoprim in patients with severe renal impairment (estimated creatinine clearance &lt;30 mL/min).</p> \n<p><b>Discussion</b> Varenicline U.S. prescribing information recommends a dose reduction in patients with severe renal impairment regardless of trimethoprim use, but does not prohibit use in patients receiving concomitant trimethoprim.<sup>1</sup> In contrast, the Canadian product labeling recommends avoiding concomitant use of varenicline and trimethoprim in patients with severe renal impairment (estimated creatinine clearance &lt;30 mL/min).<sup>2</sup> Varenicline undergoes renal elimination primarily by glomerular filtration and by active tubular secretion. In vitro studies have demonstrated that the organic cation transporter, OCT2, may mediate varenicline renal tubular secretion.<sup>1</sup> Some in vitro studies suggest that trimethoprim inhibits OCT2.<sup>3,4</sup><br><br>Considering varenicline systemic exposure is increased approximately 2-fold in patients with severe renal impairment, it would seem prudent to consider monitoring for increased varenicline adverse effects in this patient population, particularly with concomitant use of drugs (e.g., trimethoprim) that may impair its clearance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Chantix (varenicline). New York, NY: Pfizer Inc., July 2011.</p>\n<p>2. Product monograph. Champix (varenicline). Kirkland, Quebec: Pfizer Canada Inc., May 2010.</p>\n<p>3. Urakami Y, Kimura N, Okuda M, et al, “Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney,” <i>Pharm Res</i>, 2004, 21(6):976-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15212162\">[PubMed 15212162]</a></p>\n<p>4. Barendt WM and Wright SH, “The Human Organic Cation Transporter (hOCT2) Recognizes the Degree of Substrate Ionization,” <i>J Biol Chem</i>, 2002, 277(25):22491-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11953440\">[PubMed 11953440]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6369":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Cyproterone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Depends on cyproterone dose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cyproterone may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients receiving high dose cyproterone (eg, 300 mg/day) and who require HMG-CoA reductase inhibitor (statin) therapy, avoid use of statins metabolized by CYP3A4 (eg, simvastatin, atorvastatin) and consider avoiding fluvastatin (metabolized by CYP2C9). Consider use of pravastatin, rosuvastatin, or pitavastatin as these drugs are not appreciably metabolized via CYP-isoenzymes.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Red Yeast Rice, Simvastatin<br><b>Exceptions</b> Pitavastatin, Pravastatin, Rosuvastatin</p>\n</div> \n<p><b>Discussion</b> A case report describes a 66 year male diagnosed with rhabdomyolysis within 3 weeks of initiating cyproterone (100 mg TID) therapy.<sup>1</sup> The subject had previously been stable on multiple medications including simvastatin. Like simvastatin, cyproterone is metabolized by CYP3A4. Cyproterone Canadian product monograph warns that due to common metabolic pathways, concomitant use of high dose cyproterone (300 mg/day) with CYP3A4- metabolized statins (eg, simvastatin, lovastatin, atorvastatin) may increase the risk of statin-associated myopathy.<sup>2</sup> <br><br>Fluvastatin is metabolized primarily by CYP2C9 while pravastatin, rosuvastatin, and pitavastatin are not appreciably metabolized via CYP-isoenzymes.<sup>3</sup> Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds. In vitro studies suggest that high dose cyproterone may inhibit several CYP isoenzymes including 3A4 and 2C9.<sup>2</sup> To avoid a potential increased risk for myotoxicity, it may be prudent to consider use of pravastatin, rosuvastatin, or pitavastatin in patients who require statin therapy and are receiving high dose cyproterone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ahamed E and Bissett, “Rhabdomyolysis in Prostate Cancer-Caution in Prescribing Cyproterone Acetate with Statins,” <i>Clin Oncol (R Coll Radiol)</i>, 2004, 16(8):528-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15630845\">[PubMed 15630845]</a></p>\n<p>2. Product monograph. Androcur (cyproterone). Toronto, Ontario: Bayer Inc., February 2011.</p>\n<p>3. Neuvonen PJ, Niemi M, and Backman JT, “Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80(6):565-81. [PubMed17178259]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6371":"<p><b>Title</b> Vemurafenib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of vemurafenib with a strong CYP3A4 inducer and replace with another agent when possible. If a strong CYP3A4 inducer is indicated and unavoidable, the dose of vemurafenib may be increased by 240 mg (1 tablet) as tolerated. Once the strong CYP3A4 inducer has been discontinued for two weeks, resume the vemurafenib dose initiated prior to the start of the therapy of the CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Co-administration of a strong CYP3A4 inducer significantly decreases vemurafenib serum concentration. When a single dose of vemurafenib 960 mg was administered to subjects receiving rifampin 600 mg daily, the AUC of vemurafenib decreased by 40% compared to vemurafenib 960 mg alone.<sup>1</sup> Maximum serum concentration of vemurafenib was unchanged. To maintain therapeutic vemurafenib AUC, current prescribing information recommends increasing the vemurafenib dose by 240 mg (1 tablet), as tolerated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6372":"<p><b>Title</b> Vemurafenib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of vemurafenib with strong CYP3A4 inhibitors when possible. Consider use of an alternative that is not a strong inhibitor of CYP3A4 as clinically appropriate.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> According to vemurafenib prescribing information, in vitro data show that vemurafenib is a CYP3A4 substrate.<sup>1</sup> As a result, the vemurafenib prescribing information recommends avoiding concurrent use of any strong inhibitors of CYP3A4 with vemurafenib.<sup>1</sup> Specific data from any studies with strong CYP3A4 inhibitors are not yet available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zelboraf (vemurafenib). South San Francisco, CA: Genentech USA, Inc., 07/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6373":"<p><b>Title</b> Brentuximab Vedotin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that patients receiving this combination may experience reduced exposure to the active microtubule disrupting component of this antibody drug conjugate. Patients receiving brentuximab vedotin together with a strong CYP3A4 inducer should be monitored particularly closely for clinical response to treatment.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, co-administration of rifampin (a CYP 3A4 and P-glycoprotein (P-gp) inducer) and brentuximab vedotin reduced exposure to the active monomethyl auristatin E (MMAE) component by 46%.<sup>1</sup> In vitro data show that MMAE is a substrate of both CYP 3A and P-gp.<sup>2</sup> As MMAE is both metabolized and excreted as unchanged drug, the contribution of P-gp modulation on the disposition of MMAE relative to that of CYP3A modulation is unknown.<sup>1</sup> Accordingly, caution is advised when using brentuximab vedotin together with any strong CYP 3A inducer.<sup>2</sup><br><br>The mechanism of this possible interaction is likely increased metabolism of MMAE, leading to lower concentrations/exposure of this active microtubule disrupting compound, via CYP3A4 induction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. <i>J Clin Pharmacol</i>. 2013;53(8):866-877. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23754575\">[PubMed 23754575]</a></p>\n<p>2. <i>Adcetris</i> (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics Inc; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6374":"<p><b>Title</b> Brentuximab Vedotin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring for evidence of brentuximab vedotin toxicity (e.g., neuropathy, neutropenia, etc.) in patients receiving a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, co-administration of ketoconazole (a CYP3A4 and P-glycoprotein (P-gp) inhibitor) and brentuximab vedotin increased exposure to the active monomethyl auristatin E (MMAE) component of the antibody drug conjugate by 34%.<sup>1</sup> In vitro data show that MMAE is a substrate of both CYP3A and P-gp.<sup>2</sup> As MMAE is both metabolized and excreted as unchanged drug, the contribution of P-gp modulation on the disposition of MMAE relative to that of CYP3A modulation is unknown.<sup>1</sup> Accordingly, caution and increased monitoring for adverse effects are recommended when using brentuximab vedotin together with any strong CYP 3A4 inhibitor.<sup>2</sup><br><br>The mechanism of this possible interaction is likely decreased metabolism of MMAE, leading to higher concentrations/exposure of this active microtubule disrupting compound, via CYP 3A4 inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. <i>J Clin Pharmacol</i>. 2013;53(8):866-877. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23754575\">[PubMed 23754575]</a></p>\n<p>2. <i>Adcetris</i> (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics Inc; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6375":"<p><b>Title</b> Crizotinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that concurrent use of strong CYP3A4 inhibitors should be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Concurrent administration of a single crizotinib dose with the strong CYP3A4 inhibitor ketoconazole was associated with a 3.2-fold higher crizotinib AUC and a 1.4-fold higher crizotinib maximum serum concentration (Cmax) in a study of 15 healthy volunteers who received ketoconazole 200 mg twice daily for 16 days with a single crizotinib dose (150 mg) given on day 4.<sup>1</sup> Accordingly, the crizotinib prescribing information recommends that concurrent use of crizotinib with any strong CYP3A4 inhibitor should be avoided.<sup>2</sup><br><br>The likely mechanism of this apparent interaction is inhibition of the CYP3A-mediated metabolism of crizotinib leading to increased concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xu H, O'Gorman M, Tan W, Brega N, Bello A. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. <i>Eur J Clin Pharmacol</i>. 2015;71(12):1441-1449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26381275\">[PubMed 26381275]</a></p>\n<p>2. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6376":"<p><b>Title</b> Crizotinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that concurrent use of strong CYP3A4 inducers should be avoided.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The crizotinib AUC and maximum serum concentration (Cmax) were reduced by an average of 82% and 69%, respectively, with concurrent use of the strong CYP3A4 inducer in a study of 14 healthy volunteers who received a single crizotinib dose (250 mg) on day 9 of rifampin administration (600 mg/day for 14 days).<sup>1</sup> Rifampin decreased crizotinib exposure in all subjects. The crizotinib prescribing information recommends that concurrent use of crizotinib with any strong CYP3A4 inducer should be avoided.<sup>2</sup><br><br>The likely mechanism of this apparent interaction is induction of CYP3A and an increase in crizotinib metabolism, leading to decreased crizotinib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xu H, O'Gorman M, Tan W, Brega N, Bello A. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. <i>Eur J Clin Pharmacol</i>. 2015;71(12):1441-1449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26381275\">[PubMed 26381275]</a></p>\n<p>2. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6377":"<p><b>Title</b> Crizotinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Crizotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that concurrent use of grapefruit juice should be avoided.</p> \n<p><b>Discussion</b> Although specific data regarding an interaction between grapefruit juice (GFJ) and crizotinib are not available, the crizotinib prescribing information recommends that concurrent use of crizotinib with GFJ (or any strong CYP3A4 inhibitor) should be avoided.<sup>1</sup><br><br>According to crizotinib prescribing information, concurrent administration of a single crizotinib dose (150 mg) with the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day) was associated with a 3.4-fold higher crizotinib AUC and a 1.4-fold higher crizotinib maximum serum concentration (Cmax).<sup>1</sup><br><br>The likely mechanism of this predicted interaction is inhibition of the CYP3A-mediated metabolism of crizotinib leading to increased concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6378":"<p><b>Title</b> Crizotinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Crizotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that concurrent use of St Johns Wort should be avoided.</p> \n<p><b>Discussion</b> Although specific data regarding an interaction between St Johns Wort and crizotinib are not available, the crizotinib prescribing information recommends that concurrent use of crizotinib with St Johns Wort (or any strong CYP3A4 inducer) should be avoided.<sup>1</sup><br><br>Concurrent administration of a single crizotinib dose (250 mg) with the strong CYP3A4 inducer rifampin (600 mg/day) was associated with an average 82% decrease in crizotinib AUC and an average 69% decrease in crizotinib maximum serum concentration (Cmax).<sup>1</sup> Some similar interaction with St Johns Wort could be expected considering its ability to induce CYP3A. <br><br>The likely mechanism of this predicted interaction is induction of CYP3A and an increase in crizotinib metabolism, leading to decreased crizotinib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6379":"<p><b>Title</b> Alfentanil / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of Alfentanil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with alfentanil should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like alfentanil, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as alfentanil) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6380":"<p><b>Title</b> CycloSPORINE (Systemic) / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with cyclosporine should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like cyclosporine, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as cyclosporine) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6381":"<p><b>Title</b> Dihydroergotamine / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with dihydroergotamine should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like dihydroergotamine, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as dihydroergotamine) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6382":"<p><b>Title</b> Ergotamine / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with ergotamine should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like ergotamine, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as ergotamine) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6383":"<p><b>Title</b> FentaNYL / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of FentaNYL. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with fentanyl should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like fentanyl, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as fentanyl) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6384":"<p><b>Title</b> Pimozide / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may enhance the QTc-prolonging effect of Pimozide. Crizotinib may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of crizotinib with pimozide should be avoided.</p> \n<p><b>Discussion</b> According to pimozide prescribing information, concurrent use of pimozide with drugs capable of prolonging the QTc interval (such as crizotinib<sup>1</sup>) is contraindicated due to the ability of pimozide to prolong the QTc interval.<sup>2</sup><br><br>In addition, based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like pimozide, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as pimozide) should be avoided.<sup>1</sup> The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p>2. Prescribing information. Orap (pimozide). Sellersville, PA: Teva Pharmaceuticals USA, 1/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6385":"<p><b>Title</b> QuiNIDine / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may enhance the QTc-prolonging effect of QuiNIDine. Crizotinib may increase the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with quinidine should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like quinidine, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as quinidine) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup><br><br>In addition to the pharmacokinetic interaction between these drugs, their combination is expected to increase the risk of significant QTc prolongation and serious toxicities, including the development of torsades de pointes (TdP) or other significant ventricular tachyarrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6386":"<p><b>Title</b> Sirolimus / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with sirolimus should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like sirolimus, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as sirolimus) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6388":"<p><b>Title</b> Tacrolimus (Systemic) / Crizotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Crizotinib may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Crizotinib prescribing information cautions that coadministration of crizotinib with tacrolimus should be avoided.</p> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but based on the evidence that crizotinib may reduce the metabolism of CYP3A4 substrates, like tacrolimus, crizotinib prescribing information states that coadministration with narrow therapeutic index CYP3A4 substrates (such as tacrolimus) should be avoided.<sup>1</sup><br><br>The crizotinib prescribing information reports that administration of oral midazolam (a model CYP3A substrate) to patients treated with crizotinib (250 mg twice/day x 28 days) was associated with an average 3.7-fold increase in midazolam AUC, leading to crizotinib being labeled a moderate CYP3A4 inhibitor.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xalkori (crizotinib). New York, NY: Pfizer Inc, August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6390":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Icatibant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Icatibant may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor blood pressure closely in patients receiving icatibant who had been treated with angiotensin-converting enzyme (ACE) inhibitors. Specifically monitor for evidence of increased blood pressure.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Given the bradykinin B2 receptor antagonist actions of icatibant, there is a potential for icatibant to diminish the clinical antihypertensive effects of angiotensin-converting enzyme (ACE) inhibitors,<sup>1</sup> which exert at least a portion of their clinical effects via an indirect stimulation of bradykinin receptors (i.e., via interfering with the metabolism of bradykinin, leading to increased bradykinin concentrations and effects). Specific data to confirm or refute this potential interaction are not available as patients receiving ACE inhibitors were excluded from pre-approval icatibant studies.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Firazyr (icatibant). Lexington, MA: Shire Orphan Therapies, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6391":"<p><b>Title</b> Varenicline / Quinolones</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: Canadian product monograph recommends avoiding use with levofloxacin in patients with severe renal impairment (creatinine clearance &lt;30 mL/min)</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Quinolones may increase the serum concentration of Varenicline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased varenicline adverse effects with concomitant use of quinolone antibiotics (e.g., levofloxacin, moxifloxacin), particularly in patients with severe renal impairment. Varenicline U.S. prescribing information recommends a dose reduction in patients with severe renal impairment regardless of quinolone use, but does not prohibit use in patients receiving concomitant quinolones. Varenicline Canadian product monograph recommends avoiding concomitant use with levofloxacin in patients with severe renal impairment (estimated creatinine clearance &lt;30 mL/min).</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic)*, Lomefloxacin, Moxifloxacin (Systemic)*, Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Varenicline U.S. prescribing information recommends a dose reduction in patients with severe renal impairment regardless of quinolone use, but does not prohibit use in patients receiving concomitant quinolones.<sup>1</sup> In contrast, the Canadian product labeling recommends avoiding concomitant use of varenicline and levofloxacin in patients with severe renal impairment (estimated creatinine clearance &lt;30 mL/min).<sup>2</sup> Varenicline undergoes renal elimination primarily by glomerular filtration and by active tubular secretion. In vitro studies have demonstrated that the organic cation transporter, OCT2, may mediate varenicline renal tubular secretion.<sup>1</sup> Some in vitro studies suggest that levofloxacin and moxifloxacin inhibit OCT2.<sup>3,4</sup><br><br>Considering varenicline systemic exposure is increased approximately 2-fold in patients with severe renal impairment, it would seem prudent to consider monitoring for increased varenicline adverse effects in this patient population, particularly with concomitant use of drugs that may impair its clearance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Chantix (varenicline). New York, NY: Pfizer Inc., July 2011.</p>\n<p>2. Product monograph. Champix (varenicline). Kirkland, Quebec: Pfizer Canada Inc., May 2010.</p>\n<p>3. Okuda M, Kimura N, and Inui K, “Interactions of Fluoroquinolone Antibacterials, DX-619 and Levofloxacin, with Creatinine Transport by Renal Organic Cation Transporter hOCT2,” <i>Drug Metab Pharmacokinet</i>, 2006, 21(5):432-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17072098\">[PubMed 17072098]</a></p>\n<p>4. Imamura Y, Murayama N, Okudaira N, et al, “Prediction of Fluoroquinolone-Induced Elevation in Serum Creatinine Levels: A Case of Drug-Endogenous Substance Interaction Involving the Inhibition of Renal Secretion,” <i>Clin Pharmacol Ther</i>, 2011, 89(1):81-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21124314\">[PubMed 21124314]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6392":"<p><b>Title</b> Coccidioides immitis Skin Test / Immunosuppressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The response to coccidioidin skin antigen testing may be diminished in patients receiving immunosuppressants, thus potentially increasing the risk of false negative results.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> Coccidioidin skin test prescribing information contains a warning that immunosuppressant agents may reduce the response to skin test antigens.<sup>1</sup> The presumed mechanism of this interaction is suppression of lymphocyte numbers and/or impairment of lymphocyte function by immunosuppressant agents, diminishing the capability for mounting delayed-type hypersensitivity reactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Spherusol (coccidioides immitis spherule derived skin test antigen). San Diego, CA: Allermed Laboratories, Inc., July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6393":"<p><b>Title</b> Simvastatin / RisperiDONE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RisperiDONE may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider close monitoring for development of muscle toxicity (including rhabdomyolysis) in patients receiving simvastatin and risperidone.</p> \n<p><b>Discussion</b> Three case reports describe development of rhabdomyolysis in patients receiving simvastatin in combination with risperidone.<sup>1,2,3</sup> Most notably, in one of these cases symptoms of muscle toxicity developed within 12 days of risperidone (1 mg/day) initiation, in a 76 year old man who had been maintained on simvastatin (20 mg/day) for more than 2 years.<sup>1</sup> The other two reports present much weaker evidence of a specific drug-drug interaction between these agents, in the first case due to concomitant cyclosporine treatment<sup>2</sup> and in the second case due to a less definitive timeline of drug initiation,<sup>3</sup> among other factors.<br><br>The mechanism of this possible interaction is unclear, and it is unknown whether systemic concentrations of either drug were abnormal in any of the published cases. Additionally, some important patient characteristics (e.g., CYP2D6 geno/phenotype), which could theoretically have been determining factors in the reported reactions,<sup>3</sup> were not described. Until more specific data become available, the applicability of this interaction to the general population is questionable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patier JL, Ferrere F, Moreno-Cobo MA, et al, “Rabdomiolisis Producida por la Asociacion de Sinvastatina y Risperidona,” <i>Med Clin (Barc)</i>, 2007, 129(11):439. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17927942\">[PubMed 17927942]</a></p>\n<p>2. Vives S, Batlle M, Montane E, et al, “Rabdomiolisis e Insuficiencia Renal Aguda Secundaria a la Interaccion de Simvastatina, Ciclosporina A, y Risperidona en un Paciente Receptor de un Trasplante Alogenica de Progenitores Hematopoyeticos,” <i>Med Clin (Barc)</i>, 2008, 131(17):676. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19087798\">[PubMed 19087798]</a></p>\n<p>3. Webber MA, Mahmud W, Lightfoot JD, et al, “Rhabdomyolysis and Compartment Syndrome With Coadministration of Risperidone and Simvastatin,” <i>J Psychopharmacol</i>, 2004, 18(3):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15358990\">[PubMed 15358990]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}